cancer-stem-cells-2019-scientifictracks

Page 15

Cancer Stem Cells 2019

Journal of Medical Oncology andTherapeutics | Volume 4

July 18-19, 2019 | Valencia, Spain

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

CANCER STEM CELLS AND

ONCOLOGY RESEARCH

International Conference on

DRUG RESISTANT STEM CELLS IN CELLULAR MODELS FOR MOLECULAR SUBTYPES OF

BREAST CANCER

Nitin Telang

Palindrome Liaisons Consultants, USA

tudy rationale global expression profiling of differentially expressed genes in breast cancer has provided sci-

entifically robust rationales for molecular classification of breast cancer subtypes and for targeted treatment

options. Chemo-endocrine therapy combined with pathway selective small molecule inhibitors represents

common treatment of choice. However, this option is frequently associated with emergence of drug resistant

stem cells that favor progression of therapy resistant disease. This limitation emphasizes development of can-

cer stem cell models that are capable of identifying testable therapeutic alternatives against drug resistant

stem cells. Experimental approach experiments on cellular models for Luminal A, HER-2 enriched and triple

negative breast cancer subtypes were designed to isolate and characterize stem cell phenotypes resistant to

clinically relevant chemo-endocrine therapeutics and examine the mechanistic efficacy of natural products on

drug sensitive and drug resistant phenotypes. Study outcome parental MCF-7 (Luminal A), 184-B5/HER (HER-2

enriched) and MDA-MB-231 (Triple negative) cells exhibited progressive growth in the presence of cytotoxic

concentrations of Tamoxifen (TAM), Lapatinib (LAP) and Doxorubicin (DOX), respectively. Long-term treatment

with these drugs favored emergence of drug resistant TAM-R, LAP-R and DOX-R phenotypes. These resistant

cells exhibited up regulated expression of stem cell specific tumor spheroid formation and CD44 (cellular) and

Oct-4 and NANOG (molecular) markers. Treatment of drug sensitive and resistant cells with select nutritional

herbs, vitamin A derivative and natural terpenoid induced inhibition of tumor spheroid formation and down

regulated expression of CD44, Oct-4 and NANOG. Study conclusions present cancer stem cell models provide

a novel approach to identify natural products as testable alternatives for stem cell targeted therapy of che-

mo-endocrine therapy resistant breast cancer.

Nitin Telang, J Med Oncl Ther 2019, Volume 4

Nitin Telang obtained his PhD in Developmental Biology from University of Poona, India in 1974, followed by post-doctoral training

in the USA during 1976-1985. He has served as attending Biochemist at Memorial Sloan-Kettering Cancer Center, New York during

1985-1991, as an Associate Professor at Cornell University Medical College, New York during 1991-2004, and as Senior Scientist and

Director, Carcinogenesis a Prevention Laboratory at Strang Cancer Prevention Center, New York during 2004-2007. His research on

preclinical models for genetically predisposed breast and colon cancer has been funded through US Department of Defense Breast

Cancer Research Program and through US National Cancer Institute. His current research interests are in the fields of preclinical

oncology, cancer stem cell biology and anti-cancer lead compound efficacy.

BIOGRAPHY